This clinical trial, sponsored by M.D. Anderson Cancer Center, aims to evaluate the safety and efficacy of CAR.70-engineered IL15-transduced cord blood-derived NK cells in combination with lymphodepleting chemotherapy for patients with relapse/refractory hematological malignancies. The targeted patient population includes those with specific CD70 expression, which may represent a significant market opportunity given the high unmet need in hematological cancers such as leukemia, lymphoma, and multiple myeloma. The trial's focus on a novel CAR NK cell therapy positions it competitively within the expanding field of cell therapies, particularly against existing therapies that may not effectively target CD70-expressing tumors. Successful outcomes could lead to further development and commercialization, potentially enhancing M.D. Anderson's reputation as a leader in innovative cancer treatments.